Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.74 |
| ▸ | GLA | P06280 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | EDNRA | P25101 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | PPARG | P37231 | 8/20 | 0.57 |
| ▸ | RXRA | P19793 | 6/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5712301 | 1.00 | CYP1A2 (0.74) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL7927229 | 1.00 | CYP1A2 (0.74) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL8150858 | 0.88 | CYP1A2 (0.57) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL8150862 | 0.88 | CYP1A2 (0.57) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL4816472 | 0.87 | CYP1A2 (0.76) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL7929709 | 0.85 | CYP1A2 (0.70) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL7929715 | 0.85 | CYP1A2 (0.70) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL7929711 | 0.85 | CYP1A2 (0.70) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL7634637 | 0.85 | CYP1A2 (0.83) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL25371 | 0.85 | CYP1A2 (1.00) | CYP1A2MAPTMAPK1TDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1146866-B1 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | OSI PHARM INC (US) | 2006-11-29 | — | — | EP | claimed |
| EP-1146866-A4 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | OSI PHARM INC (US) | 2004-12-08 | — | — | EP | claimed |
| EP-1146866-A1 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | OSI Pharmaceuticals, Inc. (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000044372-A1 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | CELL PATHWAYS, INC. (US) | 2000-08-03 | — | — | WO | claimed |
| US-6025394-A | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols | CELL PATHWAYS, INC. (US) | 2000-02-15 | — | — | US | claimed |
| EP-1146866-B1 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | OSI PHARM INC (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1146866-A4 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | OSI PHARM INC (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1146866-A1 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | OSI Pharmaceuticals, Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6300346-B1 | THERAPY OF PRECANCEROUS LESIONS COMPRISING ADMINISTERING INDENYL HYDROXAMIC ACID DERIVATIVE COMPOUND | CELL PATHWAYS, INC. | 2001-10-09 | — | — | US | disclosed |
| US-20010020020-A1 | Method for treating patients with macular degeneration by administering substituted sulfonyl indenyl acetic acids and alcohols | PAMUKCU RIFAT (US) | 2001-09-06 | — | — | US | disclosed |
| US-20010006965-A1 | Method for treating patients with diabetic retinopathy by administering substituted sulfonyl indenyl acetic acids and alcohols | PAMUKCU RIFAT (US) | 2001-07-05 | — | — | US | disclosed |
| US-6177471-B1 | PHOSPHODIESTERASE INHIBITOR | CELL PATHWAYS, INC. | 2001-01-23 | — | — | US | disclosed |
| WO-2000044372-A1 | A METHOD FOR TREATING PATIENTS WITH ACNE BY ADMINISTERING A CYCLIC GMP PDE INHIBITOR | CELL PATHWAYS, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| US-6071934-A | PREVENTING TUMORS OR SLOWING THEIR GROWTH | CELL PATHWAYS, INC. (US) | 2000-06-06 | — | — | US | disclosed |
| US-6028116-A | Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia | CELL PATHWAYS, INC. (US) | 2000-02-22 | — | — | US | disclosed |
| US-6025394-A | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols | CELL PATHWAYS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5958982-A | Method for treating patients with sarcoidosis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols | CELL PATHWAYS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5902827-A | Method for treating patients with psoriasis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols | CELL PATHWAYS (US) | 1999-05-11 | — | — | US | disclosed |
| US-5093356-A | Antiallergens, antiasthma, antiinflammatory, cytoprotective | MERCK FROSST CANADA, INC. (CA) | 1992-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020020-A1 | Method for treating patients with macular degeneration by administering substituted sulfonyl indenyl acetic acids and alcohols | ALDH1A2, ALDH1A3, FFAR3 | CYP1A2 3426/4885MAPT 2119/4885MAPK1 3231/4885 |
| US-20010006965-A1 | Method for treating patients with diabetic retinopathy by administering substituted sulfonyl indenyl acetic acids and alcohols | ALDH1A2, ALDH1A3, IAPP | CYP1A2 3107/4885MAPT 3451/4885MAPK1 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.